Infectious Diseases Section, VA Pittsburgh Healthcare System, Pittsburgh, PA 15240, USA.
Lancet Infect Dis. 2011 Apr;11(4):301-11. doi: 10.1016/S1473-3099(10)70316-9.
Several countries have seen rising frequencies of mucormycosis among patients with haematological disorders, malignancies, or diabetes mellitus, and among transplant recipients. Growing numbers of immunocompromised hosts, widespread use of antifungal agents inactive against mucormycosis, or other unidentified factors, could be contributing to this situation. The predominant clinical manifestations of mucormycosis vary from host to host. Additionally, risk factors specific to different subgroups have been identified, such as leukaemia, allogeneic haemopoietic stem-cell transplant, voriconazole prophylaxis, diabetes, and malnutrition. We summarise the current state of knowledge of characteristics and risk factors and discuss topical developments in therapeutic methods and strategies in the management of mucormycosis.
一些国家的血液病、恶性肿瘤或糖尿病患者以及移植受者中，毛霉菌病的发病率呈上升趋势。免疫功能低下宿主的数量不断增加，抗毛霉菌病的抗真菌药物广泛使用，或其他不明因素都可能导致这种情况的发生。毛霉菌病的主要临床表现因宿主而异。此外，还确定了不同亚组特有的危险因素，如白血病、异基因造血干细胞移植、伏立康唑预防、糖尿病和营养不良。我们总结了毛霉菌病特征和危险因素的最新知识，并讨论了治疗方法和管理策略方面的最新进展。
